PTO 892 DEAFCE 1994 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE NOTICE OF REFERENCES CITED						SERIAL NUMBER 09/769,223	Art 16	Unit 48	t	nent per per		
						APPLICANTS : Benveniste, R., E., et al.						
				U.S	S. PATEN	T DOCUMENTS						
*		DOCUMENT NUMBER		DATE		NAME(S)	CLASS	ASS FILING DATE				
		Ť T										
				FO	REIGN PAT	ENT DOCUMENTS				_		
*		DOCUMENT NO. D			COUNTRY	NAME	(CLASS SUE		ASS		
*		OTHER REFERENCES (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)										
		Hoth, D. F., et al., 1994, "HIV vaccine development: a progress report", Ann. Int. Med. 8(7):603-611.										
		Stott, J., and N	. Almond,	1995,	"Assessin	g animal models of AIDS",	Nat. Me	d. 1(4)):295	-297	7.	
		Graham, B. S., and P. F. Wright, 1995, "Candidate AIDS vaccines", New Engl. J. Med. 333(20):1331-1339.										
		Haynes, B. F., et al., 1996, "Update on the issues of HIV vaccine development", Ann. Med. 28:39-41.										
		Haynes, B. F., 1996, "HIV vaccines: where we are and where we are going", Lancet 348:933-937.										
		Kent, S. J., et al., 1997, "Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection", J. Immunol. 158:807-815.										
•		Lee, TH., 1997, "Acquired immunodeficiency disease vaccines: design and development", in <i>AIDS: Biology, Diagnosis, Treatment and Prevention, fourth edition</i> , DeVita, Jr., V. T., <i>et al.</i> , eds., Lippincott-Raven Publishers, Philadelphia, PA, pp. 605-616.										
_		Letvin, N. L., 19	Letvin, N. L., 1998, "Progress in the development of an HIV-1 vaccine", Science 280:1875-1880.									
		Burton, D. R., and J. P. Moore, 1998, "Why do we not have an HIV vaccine and how can we make one?", Nat. Med. 4(5):495-498.										
									,			

^EXAMINER	DATE	* A COPY OF THIS REFERENCE IS NOT BEING FURNISHED WITH THIS OFFICE ACTION. (SEE MPEP SECTION 707.05(a).
Jeffrey S. Parkin, Ph.D.	03/05/03	PAGE 1 OF 2

PTO 892 DEA/FCE 1994 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE NOTICE OF REFERENCES CITED					SERIAL NUMBER 09/769,223 APPLICANTS : Benveni	Art U	3	to N	chment Paper lumber
			11	S PATEN	T DOCUMENTS	310, 11. 1		<u> </u>	
*	DOCUMENT NUMBER		DATE		NAME(S)	CLASS	CLASS SUBC		FILING DATE
	Ц								
	FOREIGN PATENT DOCUMENTS								
*		DOCUMENT NO.	DATE	COUNTRY	NAME		CLASS	SUBC	CLASS
		·			· · · · · · · · · · · · · · · · · · ·				
							-		
*		OTHER REFERENCES (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
	Moore, J. P., and D. R. Burton, 1999, "HIV-1 neutralizing antibodies: how full is the bottle?", Nat. Med. 5(2):142-144.								
		Nathanson, N., and B. J. Mathieson, 2000, "Biological considerations in the development of a human immunodeficiency virus vaccine", J. Infect. Dis. 182:579-589.							
		Johnston, M. I., 2000, "The role of nonhuman primate models in AIDS vaccine development", Mol. Med. 6:267-270.							
		Bende, S., and M. I. Johnston, 2000, "Update: search for an AIDS vaccine", AIDS Reader, September, 526-538.							
		Feinberg, M. B., and J. P. Moore, 2002, "AIDS vaccine models: challenging challenge viruses", Nat. Med. 8(3):207-210.							
		Shearer, G. M., and M. Clerici, 1997, "Vaccine strategies: selective elicitation of cellular or humoral immunity?", TIBTECH 15:106-109.							humoral

EXAMINER	DATE	* A COPY OF THIS REFERENCE IS NOT BEING FURNISHED WITH THIS OFFICE ACTION. (SEE MPEP SECTION 707.05(a).				
Jeffrey S. Parkin, Ph.D.	03/05/03	PAGE 2 OF 2				